37 articles
Rupatadine
Rupatadine (Rupafin) is a second-generation, once-daily oral antihistamine that blocks both H1 histamine and PAF receptors, used for allergic rhinitis and urticaria; 10 mg dose, CYP3A4-metabolized, desloratadine-forming, ranked highly among oral antihistamines.
Setipiprant
Setipiprant (ACT-129968), an oral selective CRTH2 (DP2) antagonist developed by Actelion for allergy and trialed for male pattern hair loss; safe but failed efficacy in Phase 3 rhinitis and Phase 2a alopecia trials.
SUN-1334H
SUN-1334H (SUN 1334H) was a potent, selective H1 antihistamine from India's SPARC (Sun Pharma), developed for allergic rhinitis and conjunctivitis; it reached Phase 2 in the US and was abandoned in 2013 as not viable.
Thenalidine
Thenalidine (thenophenopiperidine, AS 716, Sandostene) is a withdrawn piperidine H1-antihistamine introduced in 1953 for allergic and dermatologic conditions; severe neutropenia cases led to US withdrawal in 1958 and later withdrawals elsewhere.
Tranilast
Tranilast (Rizaben, トラニラスト) is an antiallergic, antifibrotic mast-cell stabilizer that suppresses TGF-β; approved in Japan, South Korea, and China for asthma and keloids, and in EMA/FDA orphan development for IPF.
Tripelennamine
Tripelennamine (Pyribenzamine) is a first-generation ethylenediamine H1-antihistamine approved by the FDA in 1948 for itching, hay fever, rhinitis, asthma, and urticaria; systemic forms are discontinued, with a 1% topical cream marketed since 2025.
Tritoqualine
Tritoqualine (Hypostamine, Livalfa, Inhibostamin), ATC R06AX21, is an isoquinoline histidine decarboxylase inhibitor with no H1 receptor action, used for allergic rhinitis and studied for anesthesia-related histamine reactions.